|Bid||6.10 x 1000|
|Ask||6.50 x 100|
|Day's range||6.44 - 7.03|
|52-week range||4.10 - 15.02|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.80|
Five New York City doctors were arrested Friday on charges that they accepted bribes and kickbacks from an Arizona-based pharmaceutical company to prescribe large volumes of a highly addictive painkiller. ...
Federal prosecutors on Friday brought charges against five New York doctors accused of taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company's potent fentanyl-based cancer pain medication. An indictment filed in Manhattan federal court said Gordon Freedman, Jeffrey Goldstein, Todd Schlifstein, Dialecti Voudouris and Alexandru Burducea received fees from Insys to participate as speakers in sham educational events.
A Rhode Island doctor who took kickbacks from Insys Therapeutics Inc. officials for prescribing the company’s highly addictive liquid version of the opioid painkiller Fentanyl was sentenced to more than ...
On a per-share basis, the Chandler, Arizona-based company said it had a loss of 65 cents. Losses, adjusted for pretax expenses and stock option expense, were 20 cents per share. The specialty pharmaceutical ...
The pharmaceutical company has lost top executives and a chunk of its market cap amid allegations of a conspiracy to illegally distribute an addictive prescription painkiller. But it hasn’t lost all of ...
Pain management is a potential gold mine for drug companies—and unscrupulous doctors. For patients, it can be a deadly trap of opioid painkiller addiction.
In the earlier part of this series, we briefly discussed why investors have recently rushed into cryptocurrencies and marijuana. In this part, we’ll discuss the difference between these investment opportunities, starting with the marijuana industry (MJX). Businesses exist to provide value to an end user, and marijuana’s end use has been fairly well-established. There has been an established market for medical marijuana in several countries.
In the previous article in this series, we saw that Vermont decriminalized recreational marijuana on January 22, 2018. With no legality covering the sale of marijuana and no tax revenues from these sales, what would motivate Vermont to legalize recreational marijuana?
On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.
In the previous part of this series, we saw how the legalization of recreational marijuana could create related business opportunities. In this part, we’ll discuss the potential upside of recreational marijuana for a country like Canada. According to Deloitte, recreational marijuana alone could be a $5 billion industry initially, and it could go as high as $8.7 billion.
In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.
In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy. With too much confusion surrounding the legalities of the marijuana industry, some seasoned players appear highly optimistic about the future of recreational marijuana. Late last year, Constellation Brands (STZ) agreed to acquire a 9.9% stake in the Canada-based Canopy Growth for about $191.3 million.
In this part, we look at the secondary use of marijuana, recreational use. In mid-2018, Canada is expected to make marijuana legal for recreational use. This outlook has been driving stocks such as Aurora Cannabis (ACB.TO), Canopy Growth (WEED.TO), Aphria (APH.TO), and MedReleaf (LEAF.TO) to new highs.
It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014. Globally, the acceptance of marijuana evolved further in 2017 with more countries either legalizing cannabis access at a federal level or exploring the possibility of legalizing cannabis.
Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.
Should You Jump on the Marijuana Bandwagon? Investors interested in accessing the marijuana industry have several options. In the US, Scotts Miracle-Gro (SMG) has invested in companies that are positioned to serve the cannabis market.
In December 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees, which included the company’s former president, CEO, and director Michael Babich. This indictment was on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, and conspiracy to violate the anti-kickback statute.